{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:59:37Z","timestamp":1773107977743,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ejmech.2017.03.085","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T16:24:01Z","timestamp":1491323041000},"page":"147-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Identification of 3-substituted-6-(1-(1 H -[1,2,3]triazolo[4,5- b ]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization"],"prefix":"10.1016","volume":"134","author":[{"given":"Fei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le-Duo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong-Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Xin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.03.085_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1126\/science.1846706","article-title":"Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product","volume":"251","author":"Bottaro","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2017.03.085_bib2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jcp.21183","article-title":"The met receptor tyrosine kinase in invasion and metastasis","volume":"213","author":"Benvenuti","year":"2007","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2017.03.085_bib3","first-page":"5085","article-title":"Suppression of Met expression: a possible cancer treatment","volume":"9","author":"Shinomiya","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.03.085_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2017.03.085_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1359-6101(01)00029-6","article-title":"Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition","volume":"13","author":"Maulik","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2017.03.085_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/0008-5472.CAN-06-1147","article-title":"c-MET overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion","volume":"67","author":"Sawada","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.03.085_bib7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2002.20.6.1544","article-title":"Overexpression of c-MET as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation","volume":"20","author":"Cheng","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.03.085_bib8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.20598","article-title":"c-MET overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2\/neu","volume":"113","author":"Lengyel","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.03.085_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000092716","article-title":"Effect of c-MET expression on survival in head and neck squamous cell carcinoma","volume":"27","author":"Lo Muzio","year":"2006","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2017.03.085_bib10","first-page":"1477","article-title":"Overexpression of c-MET as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation","volume":"19","author":"Drebber","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2017.03.085_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2017.03.085_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2017.03.085_bib13","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.085_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1871520614666140902153840","article-title":"A\u00a0novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy fot the treatment of multiple solid tumors: Cabozantinib","volume":"15","author":"Roy","year":"2015","journal-title":"Anti-Cancer Agent Me"},{"key":"10.1016\/j.ejmech.2017.03.085_bib15","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.085_bib16","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bmcl.2015.02.002","article-title":"Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors","volume":"25","author":"Dorsch","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.03.085_bib17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.bmcl.2009.12.109","article-title":"Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors","volume":"20","author":"Nishii","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.03.085_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2014.05.012","article-title":"SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in\u00a0vitro and in\u00a0vivo","volume":"351","author":"Wang","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2017.03.085_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-016-2058-y","article-title":"Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells","volume":"16","author":"Park","year":"2016","journal-title":"BMC cancer"},{"key":"10.1016\/j.ejmech.2017.03.085_bib20","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","article-title":"A\u00a0novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3","volume":"17","author":"Liu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.03.085_bib21","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"Jia","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.085_bib22","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1158\/1535-7163.MCT-15-0871","article-title":"In\u00a0vitro and in\u00a0vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models","volume":"15","author":"Hughes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2017.03.085_bib23","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1016\/j.bmc.2016.07.019","article-title":"Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase","volume":"24","author":"Zhao","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.085_bib24","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.110.032375","article-title":"Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications","volume":"38","author":"Diamond","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.03.085_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ejmech.2012.02.016","article-title":"Design, synthesis and molecular docking studies of some novel spiro[indoline-3,4\u2019-piperidine]-2-ones as potential c-Met inhibitors","volume":"50","author":"Ye","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.085_bib26","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/jm800043g","article-title":"Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase","volume":"51","author":"Albrecht","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.03.085_bib27","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/ci500268s","article-title":"Molecular modeling of exquisitely selective c-Met inhibitors through 3D-QSAR and molecular dynamics simulations","volume":"54","author":"Yuan","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417302532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417302532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T19:57:21Z","timestamp":1535918241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417302532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":27,"alternative-id":["S0223523417302532"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.03.085","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.03.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}